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Purpose/objectives. To assess the biochemical non-evidence of disease survival (bNEDs), disease free survival (DFS), and overall
survival (OS) rates, as well as the identiﬁcation of prognostic factors associated with these three outcomes in a popula-
tion of extreme-risk prostate cancer patients in the context of a multi-institutional Spanish database of prostate cancer
(RECAP).
Materials/methods. Predictive variables included age, Gleason score, T stage, number of very-high risk criteria, ECOG performance
score, androgen deprivation therapy (ADT) and radiation dose. Unadjusted and adjusted hazard ratios were calculated using the
Cox regression model. Survival estimates were determined using Kaplan–Meier methods.
Results. One thousand and seventy patients met the extreme-risk criteria within the RECAP database. Median age was 68 years
(range: 47–86), initial PSA was <20 in 399 patients (38%), 20–50 in 408 (39%) and >50 in 241 (23%). Thirty-two percent of patients
were T1-T2c stage, 31% T3a and 37% T3b–T4. Thirty-nine percent had Gleason score 8–10. Median radiation dose to prostate was
74Gy (range: 54–82.4Gy). Whole pelvic irradiation was administered in 47%, and 94% received ADT. With a median follow-up
of 61 months, the 5-year and 10-year bNEDs were 75.5% and 51% respectively, 89% and 77% for DFS and 92% and 64.5% for
OS. On multivariate analysis PSA higher than 50ng/ml (p=0.016), 2 very high risk criteria (p=0.05) and lack of ADT (p=0.002)
were independent prognostic factors for biochemical control. Five and 10 years bNEDs were 78.5% and 54.5% for patients with
PSA≤50 vs 66.8% and 42.3% for PSA>50, 82.9% and 48.1% for patients with 2 or more high risk criteria vs 66.1% and 45% for
patients with 2 very high risk criteria, and 77.7% and 57.4% for patients treated with ADT vs 55.1% and 18.1% for patients without
ADT.
Conclusions. Extreme-risk prostate cancer patients treated with EBRT and ADT have acceptable long term DFS and OS rates.
Patients presenting at diagnosis with 2 very high risk criteria and PSA>50ng/ml are at higher risk for biochemical failure. Such
patients should be considered for more aggressive treatments.
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